In Deep Brain Stimulation, Sapiens Adopts Wise Model

In early June, young company Sapiens Steering Brain Stimulation raised the largest Series A round that a device company in Europe, perhaps even in they US, has enjoyed in five years. Sapiens aims to solve several key challenges hindering deep brain stimulation: divorcing the therapeutic effect of stimulation from the unintended side effects, making the device MRI-compatible and providing physicians with an integrated image-guided procedure.

In early June, young company Sapiens Steering Brain Stimulation BV raised €13 million ($18.6 million) from its Series A round, co-led by Wellington Partners and Edmond de Rothschild Investment Partners. [See Deal] Life Sciences Partners also participated. The financing was the largest Series A round for a European device company since 2005, and it certainly ranks near the top of the list of Series A device financings on the other side of the Atlantic as well. The company has a preclinical stage device in an emerging field, so the vote of confidence on the part of early stage investors is all the more unusual.

But like many start-ups funded these days, Sapiens is older than it looks. Founded in 2011, the company had a four-plus year head start in the folds of the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By 

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Industry Execs Talk Tariff Turbulence During MD&M East

 

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

More from Geography

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By 

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

FDA Draft Guidance Introduces Electric Submission For Q-Sub Process

 

The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.